新的抗生素(gepotidacin)在试验中显示92%的抗药性抗淋病效果。 New antibiotic, gepotidacin, shows 92% effectiveness against drug-resistant gonorrhea in trials.

研究人员开发了一种新的抗生素 -- -- gepotidacin,在治疗抗药性淋病方面很有希望。 Researchers have developed a new antibiotic, gepotidacin, which shows promise in treating drug-resistant gonorrhea. 在第三阶段试验中,该药片92%有效,针对细菌生存所需的关键酶。 In a Phase 3 trial, the pill was 92% effective, targeting key enzymes the bacteria need to survive. 如果得到批准,这将是二十多年来淋病抗生素的第一新类别。 If approved, it would be the first new class of antibiotic for gonorrhea in over two decades. 尽管有效,但资金有限和抗药性菌株增多等挑战突出表明需要继续开展研究。 Though effective, challenges like limited funding and the rise of resistant strains highlight the need for continued research.